Han Lin, Wei Xiu-Xiu, Zheng Yu-Jiao, Zhang Li-Li, Wang Xin-Miao, Yang Hao-Yu, Ma Xu, Zhao Lin-Hua, Tong Xiao-Lin
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053 China.
Beijing University of Chinese Medicine, Beijing, 100029 China.
Chin Med. 2020 Jul 30;15:78. doi: 10.1186/s13020-020-00360-8. eCollection 2020.
Coronavirus disease 2019 (COVID-19) is a new global public health emergency. The therapeutic benefits of Cold‒Damp Plague Formula (CDPF) against COVID-19, which was used to treat "cold‒dampness stagnation in the lung" in Trial Versions 6 and 7 of the "Diagnosis and Treatment Protocol for COVID-19", have been demonstrated, but the effective components and their mechanism of action remain unclear.
In this study, a network pharmacology approach was employed, including drug-likeness evaluation, oral bioavailability prediction, protein‒protein interaction (PPI) network construction and analysis, Gene Ontology (GO) terms, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation, and virtual docking, to predict the bioactive components, potential targets, and molecular mechanism of CDPF for COVID-19 treatment.
The active compound of herbs in CDPF and their candidate targets were obtained through database mining, and an herbs-ingredients-targets network was constructed. Subsequently, the candidate targets of the active compounds were compared to those relevant to COVID-19, to identify the potential targets of CDPF for COVID-19 treatment. Subsequently, the PPI network was constructed, which provided a basis for cluster analysis and hub gene screening. The seed targets in the most significant module were selected for further functional annotation. GO enrichment analysis identified four main areas: (1) cellular responses to external stimuli, (2) regulation of blood production and circulation, (3) free radical regulation, (4) immune regulation and anti-inflammatory effects. KEGG pathway analysis also revealed that CDPF could play pharmacological roles against COVID-19 through "multi components‒multi targets‒multi pathways" at the molecular level, mainly involving anti-viral, immune-regulatory, and anti-inflammatory pathways; consequently, a "CDPF-herbs-ingredients-targets-pathways-COVID-19" network was constructed. In hub target analysis, the top hub target IL6, and ACE2, the receptor via which SARS-CoV-2 typically enters host cells, were selected for molecular docking analyses, and revealed good binding activities.
This study revealed the active ingredients and potential molecular mechanism by which CDPF treatment is effective against COVID-19, and provides a reference basis for the wider application and further mechanistic investigations of CDPF in the fight against COVID-19.
2019冠状病毒病(COVID-19)是一种新的全球突发公共卫生事件。寒湿疫方(CDPF)对COVID-19具有治疗作用,该方在《新型冠状病毒肺炎诊疗方案(试行第六版、第七版)》中用于治疗“寒湿郁肺证”,但其有效成分及其作用机制尚不清楚。
本研究采用网络药理学方法,包括药物相似性评价、口服生物利用度预测、蛋白质-蛋白质相互作用(PPI)网络构建与分析、基因本体论(GO)术语和京都基因与基因组百科全书(KEGG)通路注释以及虚拟对接,以预测CDPF治疗COVID-19的生物活性成分、潜在靶点和分子机制。
通过数据库挖掘获得了CDPF中草本植物的活性化合物及其候选靶点,并构建了药物-成分-靶点网络。随后,将活性化合物的候选靶点与COVID-19相关靶点进行比较,以确定CDPF治疗COVID-19的潜在靶点。随后构建了PPI网络,为聚类分析和枢纽基因筛选提供了依据。选择最显著模块中的种子靶点进行进一步的功能注释。GO富集分析确定了四个主要领域:(1)细胞对外界刺激的反应;(2)血液生成和循环的调节;(3)自由基调节;(4)免疫调节和抗炎作用。KEGG通路分析还表明,CDPF可在分子水平上通过“多成分-多靶点-多通路”对COVID-19发挥药理作用,主要涉及抗病毒、免疫调节和抗炎通路;因此,构建了“CDPF-药物-成分-靶点-通路-COVID-19”网络。在枢纽靶点分析中,选择排名靠前的枢纽靶点白细胞介素6(IL6)以及严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进入宿主细胞的典型受体血管紧张素转换酶2(ACE2)进行分子对接分析,结果显示出良好的结合活性。
本研究揭示了CDPF治疗COVID-19有效的活性成分和潜在分子机制,为CDPF在抗击COVID-19中的更广泛应用和进一步的机制研究提供了参考依据。